Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary
Journal of the Canadian Association of Gastroenterology · 05.11.2021 · 4 (Supplement_2) · S1-S9
DOI: 10.1093/jcag/gwab027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Canadian Association of Gastroenterology, online erschienen am 05.11.2021. Verfasst von M Ellen Kuenzig und 31 weiteren Autor:innen. Beteiligte Einrichtung: SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario,…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Crohn's and Colitis Canada, Canadian Institutes of Health Research, Pfizer.
Abstract (Originalsprache)
Persons with inflammatory bowel disease (IBD) make up more than 0.75% of the Canadian population in 2021. Early in the COVID-19 pandemic, individuals with IBD, particularly those on immunosuppressive therapies, were concerned that their health status may place them at higher risk of contracting COVID-19 or experiencing more severe disease course if infected with SARS-CoV-2. In response, Crohn’s and Colitis Canada developed the COVID-19 and IBD Taskforce in March 2020 to rapidly synthesize the evolving knowledge of COVID-19 as relevant to Canadians with IBD. The Taskforce communicated expert information directly to the Canadian IBD community through online tools and a webinar series. In order to understand the full impact of COVID-19 on the IBD community, Crohn’s and Colitis Canada commissioned a policy report that was informed through a systematic literature review and synthesized across working groups along the following domains: Epidemiology, Children and Expectant Mothers with IBD, Seniors with IBD, Mental Health, Risk Factors and Medications, Vaccines, and Healthcare Delivery during the Pandemic and the Future Model of IBD Care. This report from Canadian physicians, researchers, and IBD community representatives highlights the physical, mental, and health systems impact of COVID-19 on the entire spectrum of the IBD community, including children, adolescents, adults, seniors, and pregnant people with IBD. This executive summary provides an overview of the crucial information from each of the chapters of the policy report, supplemented with additional information made available through Crohn’s and Colitis Canada’s webinar-based knowledge translation platform.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Child Health Evaluative Sciences, SickKids Research Institute, Toronto, Ontario, Canada.
- Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
- Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
- University of Manitoba IBD Clinical and Research Centre, Winnipeg, Manitoba, Canada.
ORCID-Profile: M Ellen Kuenzig, Joseph W Windsor, Charles N Bernstein, Usha Chauhan, Stephanie Coward, Peter L Lakatos, Geoffrey C Nguyen, Cynthia H Seow, Harminder Singh, Parul Tandon, Eric I Benchimol, Gilaad G Kaplan
Förderung
- Crohn's and Colitis Canada
- Canadian Institutes of Health Research
- Pfizer
- AbbVie Corporation
- Takeda Canada Inc.
Zitieren
APA
Ellen Kuenzig, M., Windsor, J. W., Barrett, L., Bernstein, C. N., Bitton, A., Carroll, M. W., Chauhan, U., Coward, S., Fowler, S., Ghia, J. E., Geist, R., Gibson, D. L., Graff, L. A., Griffiths, A. M., Guoxian Huang, J., Jones, J. L., Khanna, R., Lakatos, P. L., Lee, K., …, & Kaplan, G. G. (2021). Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary. Journal of the Canadian Association of Gastroenterology, 4(Supplement_2), S1-S9. https://doi.org/10.1093/jcag/gwab027
Vancouver
Ellen Kuenzig M, Windsor JW, Barrett L, Bernstein CN, Bitton A, Carroll MW, et al. Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary. Journal of the Canadian Association of Gastroenterology. 2021;4(Supplement_2):S1-S9. doi:10.1093/jcag/gwab027
BibTeX
@article{EllenKuenzig2021,
author = {Ellen Kuenzig, M and Windsor, Joseph W and Barrett, Lisa and Bernstein, Charles N and Bitton, Alain and Carroll, Matthew W and Chauhan, Usha and Coward, Stephanie and Fowler, Sharyle and Ghia, Jean-Eric and Geist, Rose and Gibson, Deanna L and Graff, Lesley A and Griffiths, Anne M and Guoxian Huang, James and Jones, Jennifer L and Khanna, Reena and Lakatos, Peter L and Lee, Kate and Mack, David R and Marshall, John K and Mukhtar, Mariam S and Murthy, Sanjay K and Nguyen, Geoffrey C and Panaccione, Remo and Seow, Cynthia H and Singh, Harminder and Tandon, Parul and Targownik, Laura E and Zelinsky, Sandra and Benchimol, Eric I and Kaplan, Gilaad G},
title = {Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary},
journal = {Journal of the Canadian Association of Gastroenterology},
year = {2021},
volume = {4},
number = {Supplement_2},
pages = {S1--S9},
doi = {10.1093/jcag/gwab027}
}
EUVIMED